YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

SEHK:1558 Rapporto sulle azioni

Cap. di mercato: HK$8.7b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

YiChang HEC ChangJiang Pharmaceutical Gestione

Gestione criteri di controllo 3/4

YiChang HEC ChangJiang Pharmaceutical's Il CEO è Juncai Jiang, nominato in May2015, e ha un mandato di 9.25 anni. la retribuzione annua totale è CN¥ 2.57M, composta da 18.7% di stipendio e 81.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.008% delle azioni della società, per un valore di HK$ 670.57K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 7.1 anni e 7.1 anni.

Informazioni chiave

Juncai Jiang

Amministratore delegato

CN¥2.6m

Compenso totale

Percentuale dello stipendio del CEO18.7%
Mandato del CEO9.3yrs
Proprietà del CEO0.008%
Durata media del management7.1yrs
Durata media del Consiglio di amministrazione7.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Popularity With Investors Under Threat As Stock Sinks 26%

May 29
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Popularity With Investors Under Threat As Stock Sinks 26%

Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?

Apr 23
Do YiChang HEC ChangJiang Pharmaceutical's (HKG:1558) Earnings Warrant Your Attention?

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce

Mar 01
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce

Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%

Mar 01
Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't

Jan 03
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't

YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt

Sep 25
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt

Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?

Nov 25
Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?

Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?

Mar 23
Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?

Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?

Oct 29
Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?

Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden

Apr 13
Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially

Mar 23
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially

YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.

Mar 13
YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.

YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?

Feb 20
YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?

Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?

Feb 02
Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Dec 26
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend

Dec 13
Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend

What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Nov 30
What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Juncai Jiang rispetto agli utili di YiChang HEC ChangJiang Pharmaceutical?
DataCompenso totaleStipendioGuadagni aziendali
Dec 31 2023CN¥3mCN¥482k

CN¥2b

Sep 30 2023n/an/a

CN¥2b

Jun 30 2023n/an/a

CN¥1b

Mar 31 2023n/an/a

CN¥608m

Dec 31 2022CN¥1mCN¥600k

CN¥77m

Sep 30 2022n/an/a

-CN¥18m

Jun 30 2022n/an/a

-CN¥113m

Mar 31 2022n/an/a

-CN¥351m

Dec 31 2021CN¥1mCN¥490k

-CN¥588m

Sep 30 2021n/an/a

-CN¥436m

Jun 30 2021n/an/a

-CN¥285m

Mar 31 2021n/an/a

CN¥277m

Dec 31 2020CN¥756kCN¥229k

CN¥839m

Sep 30 2020n/an/a

CN¥1b

Jun 30 2020n/an/a

CN¥2b

Mar 31 2020n/an/a

CN¥2b

Dec 31 2019CN¥393kCN¥222k

CN¥2b

Sep 30 2019n/an/a

CN¥2b

Jun 30 2019n/an/a

CN¥1b

Mar 31 2019n/an/a

CN¥1b

Dec 31 2018CN¥365kCN¥209k

CN¥943m

Sep 30 2018n/an/a

CN¥961m

Jun 30 2018n/an/a

CN¥980m

Mar 31 2018n/an/a

CN¥813m

Dec 31 2017CN¥324kCN¥194k

CN¥647m

Compensazione vs Mercato: La retribuzione totale di Juncai ($USD 360.29K ) è circa la media per le aziende di dimensioni simili nel mercato Hong Kong ($USD 473.40K ).

Compensazione vs guadagni: La retribuzione di Juncai è aumentata di oltre il 20% nell'ultimo anno.


AMMINISTRATORE DELEGATO

Juncai Jiang (42 yo)

9.3yrs

Mandato

CN¥2,572,000

Compensazione

Mr. Juncai Jiang has been General Manager and Executive Director of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. since joining in May 2015. Mr. Jiang served as Deputy Head of the traditional Chinese med...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Juncai Jiang
GM & Executive Director9.3yrsCN¥2.57m0.0076%
CN¥ 662.6k
Yangui Chen
Head of the Sales Department10.3yrsCN¥645.00kNessun dato
Danjin Wang
Deputy GM & Executive Director9.3yrsCN¥2.71m0.0076%
CN¥ 666.9k
Shuang Li
Deputy GM & Executive Director9.3yrsCN¥1.32m0.0076%
CN¥ 662.6k
Hao Chen
Executive Directorless than a yearCN¥1.59mNessun dato
Qiang Zhang
CFO & Head of Finance Department5.5yrsCN¥480.38kNessun dato
Shengchao Wang
Chief of Quality Division & Employee Representative Supervisor7.1yrsNessun dato0.0036%
CN¥ 317.7k
Qiyun Peng
Joint Company Secretary5.8yrsCN¥370.31kNessun dato
Wai Chiu Wong
Joint Company Secretary2.5yrsNessun datoNessun dato

7.1yrs

Durata media

43yo

Età media

Gestione esperta: Il team dirigenziale di 1558 è esperto e expertise (durata media dell'incarico 7.1 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Juncai Jiang
GM & Executive Director9.3yrsCN¥2.57m0.0076%
CN¥ 662.6k
Danjin Wang
Deputy GM & Executive Director18.5yrsCN¥2.71m0.0076%
CN¥ 666.9k
Shuang Li
Deputy GM & Executive Director6.2yrsCN¥1.32m0.0076%
CN¥ 662.6k
Hao Chen
Executive Directorless than a yearCN¥1.59mNessun dato
Shengchao Wang
Chief of Quality Division & Employee Representative Supervisor7.1yrsNessun dato0.0036%
CN¥ 317.7k
Xinfa Tang
Non-Executive Chairman9.3yrsCN¥32.19m0.015%
CN¥ 1.3m
Jianxin Tang
Independent Non-Executive Director9.3yrsCN¥100.00kNessun dato
Zhonghua Luo
Supervisor7.2yrsNessun dato0.0076%
CN¥ 662.6k
Jinlong Tang
Chairman of the Board of Supervisors5.2yrsNessun datoNessun dato
Ling Xiang
Independent Non Executive Director4.2yrsCN¥100.00kNessun dato
Xuechen Li
Independent Non-Executive Director3.9yrsCN¥340.00k0.00045%
CN¥ 39.3k

7.1yrs

Durata media

46yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 1558 sono considerati esperti (durata media dell'incarico 7.1 anni).